Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.60 |
| ▸ | DRD2 | P14416 | 15/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2745799 | 0.99 | DRD3 (0.59) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2745539 | 0.98 | DRD3 (0.60) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2745366 | 0.98 | DRD3 (0.59) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2744599 | 0.89 | DRD3 (0.51) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2745499 | 0.88 | DRD3 (0.51) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2744907 | 0.88 | DRD3 (0.52) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2745161 | 0.88 | DRD3 (0.48) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2745086 | 0.88 | DRD3 (0.51) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2745383 | 0.88 | DRD3 (0.49) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2745409 | 0.87 | DRD3 (0.47) | DRD3KCNH2DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203445-B1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-11-27 | — | — | EP | claimed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | claimed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | claimed |
| EP-2203445-B1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-11-27 | — | — | EP | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178549-B2 | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2010-08-19 | — | — | US | disclosed |
| EP-2203445-A1 | AZABICYCLO Ý3. 1. O¨HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | Glaxo Group Limited (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009043883-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043883-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210672-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR5A, DRD5 | DRD3 1/4885KCNH2 344/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.